---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036278"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T02:34:18.861120+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation

## Summary
- Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.
- Cash of $47.8M at Dec 31, 2024 plus $5.5M from Jan 2025 close; funds operations into Q1 2027.
- OpRegen (dry AMD/GA) received FDA RMAT designation; positive 24-month visual acuity data reported.
- OPC1 DOSED study initiated Feb 2025 in spinal cord injury; UC San Diego Health first site.
- Closed financings for $44M gross proceeds; potential $36M from milestone-linked warrants.

## SEC filing metadata
- accession: 0000950170-25-036278
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/0000950170-25-036278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/lctx-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036278
- JSON: https://secwatch.observer/filing/0000950170-25-036278.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.